Related Experiment Videos
4-Ipomeanol: a novel investigational new drug for lung cancer
M C Christian1, R E Wittes, B Leyland-Jones
1Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892.
Abstract:
4-Ipomeanol (IPO) is the first agent to undergo preclinical development at the National Cancer Institute (NCI) based principally on a specific biochemical-biological rationale for clinical investigation as an antineoplastic agent targeted against lung cancer. This disease-specific development of IPO was initially stimulated by observations that the compound was activated by metabolism, preferentially within the mammalian lung, specifically within bronchiolar Clara cells, and that its predominant toxicity was to the lung in most species. IPO is inactive or only minimally active against most conventional antitumor test systems. However, some human lung cancer cell lines, as well as a variety of fresh human lung tumor biopsy specimens, have been shown to be capable of mediating the in situ biotransformation of IPO to a potentially cytotoxic intermediate. In this report, the biochemistry, metabolism, preclinical pharmacology, and toxicology of IPO are reviewed and the clinical development plans for this unique and challenging new agent are presented.
Insights
4-Ipomeanol (IPO) is a novel antineoplastic agent targeting lung cancer. It is activated in lung cells, showing potential against specific human lung tumors, with preclinical data guiding clinical development.
Area of Science:
- Biochemistry
- Pharmacology
- Toxicology
Background:
- 4-Ipomeanol (IPO) is the first agent developed by the National Cancer Institute (NCI) for lung cancer based on a specific biochemical rationale.
- IPO is activated by metabolism in mammalian lung, particularly in bronchiolar Clara cells, with lung toxicity observed in most species.
Purpose of the Study:
- To review the biochemistry, metabolism, preclinical pharmacology, and toxicology of 4-Ipomeanol (IPO).
- To present the clinical development plans for IPO as a targeted antineoplastic agent for lung cancer.
Main Methods:
- Review of preclinical data on IPO's activation, metabolism, and toxicity.
- Evaluation of IPO's efficacy against conventional antitumor test systems and human lung cancer models.
Main Results:
- IPO is minimally active in conventional antitumor systems but shows potential when activated in situ by human lung cancer cell lines and tumor biopsy specimens.
- Metabolism of IPO preferentially occurs in the mammalian lung, specifically in Clara cells, leading to a cytotoxic intermediate.
Conclusions:
- 4-Ipomeanol (IPO) represents a unique approach to lung cancer treatment, leveraging disease-specific activation and targeting.
- Further clinical development is planned for IPO, addressing its unique pharmacological profile and potential efficacy in lung cancer patients.